Matinas Biopharma (MTNB)
(Delayed Data from AMEX)
$0.09 USD
0.00 (0.00%)
Updated Aug 27, 2024 03:18 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Matinas Biopharma Holdings, Inc. [MTNB]
Reports for Purchase
Showing records 1 - 20 ( 71 total )
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
2023 Outlook-MAT2203 Has Paved Path for Nucleic Acids and Broader Collaboration Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
MAT2203 Progress-Phase 3 Initiation in CM Expected 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
MAT2203 Delivers in EnACT Trial-1Q23 Sights Focused on Phase 3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
MAT2203 Paves Way For LNC Platform, Collaboration Upside; Reit Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
MAT2203 Phase 2 EnACT Top-Line Expected 3Q22-Thoughts on Program Advancement
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
LNC Drug Delivery Platform Attracts BioNTech Collaboration
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
LNC Platform Advancement With MAT2203 Top-Line Expected 3Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
MAT2203 Leads LNC Charge-Next EnACT Cohort Topline Anticipated 3Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
MAT2203 Phase 2 EnACT Advancement Leads LNC Validation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
Initial MAT2203 Cohorts Further Validate Merits of LNC Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
LNC Platform Front and Center With EnACT Progress; Near-Term Cohort Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
Our Thoughts on R&D Day Broad Applicability for LNC Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
LNC Delivery Pipeline Rebranding; Next Sights on MAT2203 Data Expected 3Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
LNC Platform Takes Center Stage in Strategic Shift From Lypdiso; PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
Leveraging Focus on EPA Bioavailability Amid ENHANCE-IT Top Line
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
In Shifting OM3 Landscape, MAT9001 Stands Chance for Differentiated Benefit
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Matinas Biopharma Holdings, Inc.
Industry: Medical - Drugs
Considerations for the Omega-3 Landscape, and Opportunity to ENHANCE-IT; Reit Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A